World-leading capabilities in multiplexable gene editing
Join Our Team
Our Science
World-leading capabilities in multiplexable gene editing
Genome editing for immune-privileged features
Newsroom
Press Releases
Qihan Biotech announces the completion of pre-Series B financing for developing stem cell-derived cell therapy products with high-throughput multiplexable genome editing2023/09/21
Hangzhou Qihan Biotech Co., Ltd. today announced the successful completion of a pre-Series B financing exceeding $16 million.
1 / 3Press Releases
Qihan Biotechnology Presents Preclinical Data at American Association for Cancer Research Annual Meeting 20222022/04/08
NK cells derived from genetically engineered human induced pluripotent stem cells (iPSCs) hold great potential to become the next generation allogeneic cell therapy products.
1 / 3
Contact Us
Hangzhou Qihan Biotech Co., Ltd.
Address: Xiaoshan District, Hangzhou, Zhejiang, China
Zipcode: 311231
TEL: 0571-83500380
FAX: 0571-83500370